NO304831B1 - Pyrazoler og pyrazolopyrimidiner med CRF antagonist aktivitet - Google Patents

Pyrazoler og pyrazolopyrimidiner med CRF antagonist aktivitet

Info

Publication number
NO304831B1
NO304831B1 NO952395A NO952395A NO304831B1 NO 304831 B1 NO304831 B1 NO 304831B1 NO 952395 A NO952395 A NO 952395A NO 952395 A NO952395 A NO 952395A NO 304831 B1 NO304831 B1 NO 304831B1
Authority
NO
Norway
Prior art keywords
pct
pyrazoles
antagonist activity
pyrazolopyrimidines
crf antagonist
Prior art date
Application number
NO952395A
Other languages
English (en)
Norwegian (no)
Other versions
NO952395L (no
NO952395D0 (no
Inventor
William Stephen Faraci
Jr Willard Mckowan Welch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO952395D0 publication Critical patent/NO952395D0/no
Publication of NO952395L publication Critical patent/NO952395L/no
Publication of NO304831B1 publication Critical patent/NO304831B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO952395A 1992-12-17 1995-06-16 Pyrazoler og pyrazolopyrimidiner med CRF antagonist aktivitet NO304831B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99222592A 1992-12-17 1992-12-17
PCT/US1993/010359 WO1994013643A1 (fr) 1992-12-17 1993-11-03 Pyrazoles et pyrazolopyrimidines presentant une activite d'antagonistes du facteur de liberation de la cortitrophine

Publications (3)

Publication Number Publication Date
NO952395D0 NO952395D0 (no) 1995-06-16
NO952395L NO952395L (no) 1995-08-16
NO304831B1 true NO304831B1 (no) 1999-02-22

Family

ID=25538063

Family Applications (2)

Application Number Title Priority Date Filing Date
NO952395A NO304831B1 (no) 1992-12-17 1995-06-16 Pyrazoler og pyrazolopyrimidiner med CRF antagonist aktivitet
NO985494A NO306111B1 (no) 1992-12-17 1998-11-25 Pyrazoler og pyrazolopyrimidiner med CRF antagonist aktivitet

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO985494A NO306111B1 (no) 1992-12-17 1998-11-25 Pyrazoler og pyrazolopyrimidiner med CRF antagonist aktivitet

Country Status (27)

Country Link
US (1) US5712303A (fr)
EP (1) EP0674624B1 (fr)
JP (1) JP2862374B2 (fr)
KR (1) KR0170567B1 (fr)
CN (1) CN1060768C (fr)
AT (1) ATE175961T1 (fr)
AU (1) AU690527B2 (fr)
BR (1) BR9307659A (fr)
CA (1) CA2150483C (fr)
CZ (1) CZ284157B6 (fr)
DE (1) DE69323212T2 (fr)
DK (1) DK0674624T3 (fr)
EG (1) EG20397A (fr)
ES (1) ES2126661T3 (fr)
FI (1) FI113648B (fr)
GR (1) GR3029568T3 (fr)
HU (1) HUT67457A (fr)
IL (1) IL107946A (fr)
MX (2) MX9308042A (fr)
MY (1) MY131382A (fr)
NO (2) NO304831B1 (fr)
NZ (1) NZ257770A (fr)
PL (1) PL175831B1 (fr)
RU (1) RU2142946C1 (fr)
TW (1) TW238303B (fr)
WO (1) WO1994013643A1 (fr)
ZA (1) ZA939404B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US6103900A (en) * 1992-12-17 2000-08-15 Pfizer Inc Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
DE69532817T2 (de) * 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
EP0729758A3 (fr) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US5817688A (en) * 1995-12-19 1998-10-06 Rhone-Poulenc Inc. Pesticidal 1-arylpyrazole derivatives
US5922885A (en) 1995-12-19 1999-07-13 Rhone-Poulenc Inc. Pesticidal 1-arylpyrazole derivatives
US6051578A (en) * 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
ES2203937T3 (es) * 1997-03-26 2004-04-16 Taisho Pharmaceutical Co., Ltd Derivados de 4-tetrahidropiridilpirimidina.
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
WO1999045007A1 (fr) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Pyrazolo[4,3-b]pyridines antagonistes du facteur de liberation de la corticotropine (crf)
AU3375999A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino(2,3-b)indole and 5,6,7,8-tetrahydro-9h-pyrimidino(4,5-b)indole derivatives: crf1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
US6376527B1 (en) 1998-05-05 2002-04-23 Syntex (U.S.A.) Llc Pyrazole derivatives-p38 map kinase inhibitors
DE69924480D1 (en) * 1998-05-05 2005-05-04 Hoffmann La Roche Pyrazolderivative als p-38 map kinase inhibitoren
US20020156114A1 (en) 1998-05-05 2002-10-24 Goldstein David Michael Pyrazole derivatives - p38 MAP kinase inhibitors
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1129091B1 (fr) 1998-11-12 2002-10-02 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
DK1129096T3 (da) 1998-11-12 2003-09-15 Neurocrine Biosciences Inc CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
FR2789387B1 (fr) 1999-02-04 2001-09-14 Aventis Cropscience Sa Nouveau procede de preparation d'intermediaires pesticides
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6506784B1 (en) 1999-07-01 2003-01-14 3-Dimensional Pharmaceuticals, Inc. Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides
US6409988B1 (en) 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
US6518266B1 (en) 1999-07-22 2003-02-11 3-Dimensional Pharmaceuticals 1- Aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
WO2001025241A2 (fr) 1999-10-06 2001-04-12 3-Dimensional Pharmaceuticals, Inc. 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles fusionnes, leur synthese et utilisation en tant que pesticides
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CA2398956A1 (fr) * 2000-02-14 2001-08-16 Japan Tobacco Inc. Composition pharmaceutique pour la prophylaxie ou le traitement du stress post-operatoire
US6531478B2 (en) * 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
PL214231B1 (pl) 2001-04-27 2013-07-31 Eisai R & D Man Co Pochodne pirazolo [1,5-a] pirydyny, kompozycje je zawierajace oraz zastosowanie
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE10142665B4 (de) 2001-08-31 2004-05-06 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-one und ihre Derivate
KR100760072B1 (ko) * 2001-12-04 2007-09-18 에프. 호프만-라 로슈 아게 고리 축합된 피라졸 유도체
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7323569B2 (en) 2002-10-22 2008-01-29 Eisai R&D Management Co., Ltd. 7-phenylpyrazolopyridine compounds
CA2507074A1 (fr) * 2002-12-02 2004-06-17 F. Hoffmann-La Roche Ag Derives d'indazole utilises en tant qu'antagonistes de crf
JP2006513257A (ja) 2002-12-13 2006-04-20 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 線維筋痛症および他の障害を処置するためのプレガバリン誘導体
WO2004092170A2 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines et pyrazolotriazines et leurs procedes de fabrication et d'utilisation
EP1633756B1 (fr) 2003-04-09 2008-12-24 Biogen Idec MA Inc. Antagonistes de recepteur d'adenosine a2a
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
PT1641764E (pt) 2003-06-26 2011-10-27 Novartis Ag Inibidores de p38 quinase a base de heterociclo de 5 elementos
JP4681548B2 (ja) 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2555287A1 (fr) * 2004-02-18 2005-08-25 David Garrett Loughhead Modulateurs heterocycliques du recepteur gaba-a selectifs d'un sous-type
WO2005115382A1 (fr) 2004-05-29 2005-12-08 7Tm Pharma A/S Ligands des recepteurs crth2 a usages medicaux
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20060252825A1 (en) * 2005-04-22 2006-11-09 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
AR056980A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
GT200600165A (es) * 2005-04-22 2007-03-14 Derivados dihidrobenzofuranos y usos de los mismos
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CA2716080C (fr) 2008-02-20 2016-12-13 Targia Pharmaceuticals Compositions pharmaceutiques actives sur le snc et methodes d'utilisation
SI2266990T1 (sl) 2008-04-15 2013-01-31 Eisai R&D Management Co. Ltd. Spojina 3-fenilpirazolo(5,1-b)tiazola
EP2291181B9 (fr) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Utilisation de la captodiamine pour le traitement des symptômes de la dépression
AR084370A1 (es) 2009-08-07 2013-05-15 Chugai Pharmaceutical Co Ltd Derivados de aminopirazol
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
US10391081B2 (en) 2013-12-27 2019-08-27 Chugai Seiyaku Kabushiki Kaisha FGFR gatekeeper mutant gene and drug targeting same
WO2016204261A1 (fr) 2015-06-17 2016-12-22 中外製薬株式会社 Dérivés d'aminopyrazole
WO2017190086A1 (fr) 2016-04-29 2017-11-02 Fgh Biotech, Inc. Composés de pyrazole di-substitués pour le traitement de maladies
CA3036195A1 (fr) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Composes de pyrazole di-substitues pour le traitement de maladies
EP3563848A1 (fr) * 2018-04-30 2019-11-06 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Inhibiteurs de la serpine pour le traitement des maladies à prions et de type prion
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778443A (en) * 1969-02-13 1973-12-11 Ciba Geigy Ag 4-tetrahydro pyridyl,hydroxy alkyl pyrazoles
FR2460299A1 (fr) * 1979-07-05 1981-01-23 Bellon Labor Sa Roger Nouveaux derives du pyrazole et leur application therapeutique
FR2472564A1 (fr) * 1979-12-31 1981-07-03 Bellon Labor Sa Roger Nouveaux aryl-1 arylsulfonyl-4 1h-pyrazolols-3, et procede pour les preparer
DE3602728A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 51373 Leverkusen Schaedlingsbekaempfungsmittel auf basis von pyrazolderivaten
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds

Also Published As

Publication number Publication date
KR950704261A (ko) 1995-11-17
EP0674624B1 (fr) 1999-01-20
MXPA98005325A (es) 2004-08-24
CA2150483C (fr) 1999-09-14
PL175831B1 (pl) 1999-02-26
CN1092768A (zh) 1994-09-28
BR9307659A (pt) 1999-06-29
HUT67457A (en) 1995-04-28
CA2150483A1 (fr) 1994-06-23
IL107946A (en) 1998-09-24
IL107946A0 (en) 1994-04-12
JPH07509725A (ja) 1995-10-26
KR0170567B1 (ko) 1999-02-18
NO952395L (no) 1995-08-16
EG20397A (en) 1999-02-28
NO985494L (no) 1995-08-16
CN1060768C (zh) 2001-01-17
JP2862374B2 (ja) 1999-03-03
MX9308042A (es) 1994-08-31
DE69323212T2 (de) 1999-05-27
NO952395D0 (no) 1995-06-16
DK0674624T3 (da) 1999-09-13
FI113648B (fi) 2004-05-31
ES2126661T3 (es) 1999-04-01
PL309356A1 (en) 1995-10-02
GR3029568T3 (en) 1999-06-30
DE69323212D1 (de) 1999-03-04
FI935674A0 (fi) 1993-12-16
NO985494D0 (no) 1998-11-25
AU690527B2 (en) 1998-04-30
ATE175961T1 (de) 1999-02-15
WO1994013643A1 (fr) 1994-06-23
TW238303B (fr) 1995-01-11
NO306111B1 (no) 1999-09-20
RU2142946C1 (ru) 1999-12-20
CZ284157B6 (cs) 1998-08-12
HU9303591D0 (en) 1994-04-28
ZA939404B (en) 1995-06-15
NZ257770A (en) 1997-02-24
FI935674A (fi) 1994-06-18
EP0674624A1 (fr) 1995-10-04
US5712303A (en) 1998-01-27
AU5454894A (en) 1994-07-04
MY131382A (en) 2007-08-30
CZ158595A3 (en) 1996-01-17

Similar Documents

Publication Publication Date Title
NO304831B1 (no) Pyrazoler og pyrazolopyrimidiner med CRF antagonist aktivitet
FI935673A (fi) Aminosubstituoituja pyratsoleja
FI935585A0 (fi) Pyrrolopyrimidiner
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
FI952900A (fi) Polypeptidi ja siitä valmistettu anti-HIV-aine
ATE163402T1 (de) Substituierte ortho- ethenylphenylessigsäurederivate